Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12619000710123
Ethics application status
Approved
Date submitted
11/04/2019
Date registered
13/05/2019
Date last updated
9/02/2021
Date data sharing statement initially provided
13/05/2019
Type of registration
Prospectively registered
Titles & IDs
Public title
When drugs don't work: A psychological intervention for Alcohol Related Liver Disease.
Query!
Scientific title
Psychological Treatment for Alcohol Related Liver Disease: Assessing Patient Engagement, Retention, and Drinking Behaviour.
Query!
Secondary ID [1]
298119
0
None
Query!
Universal Trial Number (UTN)
U1111-1230-4489
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Alcoholic Hepatitis
312116
0
Query!
Alcohol Related Liver Disease
312117
0
Query!
Alcohol Use Disorder
312118
0
Query!
Condition category
Condition code
Oral and Gastrointestinal
310672
310672
0
0
Query!
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Query!
Mental Health
310673
310673
0
0
Query!
Addiction
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Patients are referred to this outpatient alcohol and drug service following inpatient hospital admission, by their General Practitioner, or self-referral. Initial assessment is conducted by a clinical nurse or social worker. Initial assessment includes standardised review of psychosocial history, dependency symptoms, dependence severity, and comorbid drug use. Suitable patients are enrolled in the Cognitive-Behavioural Therapy (CBT) for Alcohol Use Disorder (AUD) program. When enrolled in the program patients receive a 1-hour consult with an addiction specialist physician, comprising a medical review, physical examination, assessment of suitability for prescription of adjunct pharmacotherapy (e.g. Acamprosate or naltrexone), and a written report to their primary health-care provider with recommendations for ongoing management. The CBT for AUD program comprises 8x 1hour face-to-face outpatient sessions over 3 months with a clinical psychologist. Following three months of abstinence, less frequent contact is maintained. Breathalyser readings are mandatory and routinely undertaken prior to each session. Standardised assessments are administered each session, monitoring: drinking behaviours (quantity, frequency), adherence to adjunct pharmacotherapy, alcohol craving, and alcohol refusal self-efficacy. The first session is devoted to obtaining a thorough assessment of the problem (including a comprehensive psychometric battery), education about the potential harms associated with alcohol, and affirming commitment to alcohol abstinence for the duration of the program. A CBT intervention plan is then developed collaboratively based on individual needs. The most common targets for intervention include: identification and alteration of alcohol expectancies, enhancement of drinking refusal self-efficacy, craving management, development of alternative coping strategies, problem-solving skills training, goal setting, and lifestyle improvement.
The Tailored Alcoholic Hepatitis (AH) Intervention will match for the existing generic face-to-face CBT Intervention historical benchmark for length of treatment (3 months) and therapist contact (8 hours). When possible, AH patients will be assessed as inpatients, including 1x addiction specialist physician assessment and 1x clinical psychologist review. The clinical psychologist will outline the services available to the patient, offering the CBT for AUD program as a means of ongoing support as an outpatient. Hospital discharge is determined by the treating medical team, not this service.
Post-inpatient hospital discharge, patients will either enrol in The CBT for AUD program or receive 2 x weekly 20 min ‘booster’ telephone sessions for 3 months (totalling 8 hours). The mode of treatment delivery (face-to-face or telephone) will be determined by geographical feasibility. Face-to-face sessions are preferred. Psychometric assessment and intervention targets will not be affected by modality, though AH patients are likely to require greater emphasis on health and lifestyle factors associated with adherence to treatment for AH. Treatment adherence is determined by session attendance, psychometric assessment at each session, and patient self-report of drinking behaviour.
This study is a non-randomised trial. All patients will receive the intervention. All patients enrolled in the CBT for AUD program consent for their anonymous data to be used for program evaluation. Non-consenting patients will not be included in the dataset but will receive the intervention. Participation is voluntary and patients may withdraw a any time without penalty. Patients who do not achieve abstinence will be offered ongoing support or referral options appropriate to their condition and circumstances. Patient outcomes post the 3-month treatment period will not be included in this study.
Query!
Intervention code [1]
314009
0
Behaviour
Query!
Intervention code [2]
314010
0
Treatment: Other
Query!
Intervention code [3]
314011
0
Lifestyle
Query!
Comparator / control treatment
Historical control of AH patients referred to the Cognitive-Behavioural Therapy (CBT) program for Alcohol Use Disorder (AUD; Treatment as Usual, TAU) from 01/01/2012 to 01/01/2019. TAU is not manualised or based on specific guidelines. Clinical psychologists are trained in administration of CBT for AUD.
Query!
Control group
Historical
Query!
Outcomes
Primary outcome [1]
319741
0
Patient retention as determined by the percentage of patients engaged in treatment at each time point.
Query!
Assessment method [1]
319741
0
Query!
Timepoint [1]
319741
0
Each of 8 sessions across 12-week intervention. Time points are non-standard, though will typically occur at 7-14 day intervals.
Query!
Secondary outcome [1]
369360
0
Percentage of days alcohol is consumed between sessions. Drinking days are determined by a Time-Line Follow Back procedure conducted by psychologists during each session.
Query!
Assessment method [1]
369360
0
Query!
Timepoint [1]
369360
0
Each of 8 sessions across 12-week intervention. Time points are non-standard, though will typically occur at 7-14 day intervals.
Query!
Secondary outcome [2]
370317
0
Patient engagement as determined by the proportion of patients offered the CBT for AUD program who commence treatment relative to those who do not.
Query!
Assessment method [2]
370317
0
Query!
Timepoint [2]
370317
0
Timepoint 1: Pre-treatment assessment.
Timepoint 2: Session 1.
Time between pre-treatment assessment and session 1 is non-standard.
Query!
Eligibility
Key inclusion criteria
All Alcoholic Hepatitis (AH) patients will be diagnosed and medically managed by liver disease specialists (Hepatologists) and Addiction specialist. Liver biopsy remains the gold standard for diagnosis, however indications for physician practice varies. While biopsy is the preferred inclusion criterion, absence will not be an exclusion criterion. For patients without liver biopsy, inclusion requires 1). Consistent alcohol risk history, 2). Absence of other acute liver injury risk; 3) at least 2/3 of: jaundice < 8 weeks, AST/ALT ratio > 2; neutrophilia. Further characterised on AH severity (Maddrey Discriminant Function 32) and the presence of cirrhosis.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
As this is an effectiveness study all patients eligible for enrolment in the hospital based program will be included. Such eligibility requires patients to be able to provide written informed consent.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Patients will be unaware of updates to routine care. All patients will effectively receive the active treatment condition.
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
NA
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Other
Query!
Other design features
Historical controls.
Query!
Phase
Not Applicable
Query!
Type of endpoint/s
Efficacy
Query!
Statistical methods / analysis
The primary outcome will be assessed via logistic regression, where the outcome is completed treatment (0 = no, 1 = yes) and the independent variable is treatment group (0 = old protocol, 1 = new protocol). Potential confounding variables will be included as covariates (e.g. dependence severity). Depending on the distribution of the number of sessions attended, parametric or non-parametric statistics may be employed to determine whether more sessions were attended on average. Again, potential confounding variables will be included as covariates. Analysis of secondary secondary outcomes (drinking behaviour) will be analysed using non-parametric longitudinal mixed effects models (Multilevel Modelling). LME models are considered the gold standard in psychotherapy research as they have the advantage of modelling the trajectory of longitudinal outcomes. Missing data may therefore be imputed based on individual trajectories.
To determine non-inferiority or superiority of the new treatment protocol when the primary outcome is patient retention non-inferiority requirements were calculated in R version 3.5.0. Holding power level at 80% and alpha at 0.05, with a present response rate for patients with AH completing treatment at 30% and a modest protocol goal of 40%, a sample size of 70 patients is required to support non-inferiority within a 10% equivalence margin. Given that we have historical data for N ~130 patients, we only require 35 (70 / 2 = 35) patients to commence the new protocol for this study to be sufficiently powered.
Query!
Recruitment
Recruitment status
Recruiting
Query!
Date of first participant enrolment
Anticipated
23/05/2019
Query!
Actual
1/07/2019
Query!
Date of last participant enrolment
Anticipated
25/02/2021
Query!
Actual
Query!
Date of last data collection
Anticipated
20/05/2021
Query!
Actual
Query!
Sample size
Target
35
Query!
Accrual to date
1
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
QLD
Query!
Recruitment hospital [1]
13617
0
Princess Alexandra Hospital - Woolloongabba
Query!
Recruitment postcode(s) [1]
26279
0
4102 - Woolloongabba
Query!
Funding & Sponsors
Funding source category [1]
302298
0
Government body
Query!
Name [1]
302298
0
Metro South Health Centres for Health Research
Query!
Address [1]
302298
0
Metro South Health Research Support Coordinator and Grants Administration Office
Centres for Health Research
Level 7, Translational Research Institute
37 Kent Street
Woolloongabba QLD 4102
Query!
Country [1]
302298
0
Australia
Query!
Primary sponsor type
Government body
Query!
Name
Metro South Health
Query!
Address
Metro South Health Research Support Coordinator and Grants Administration Office
Centres for Health Research
Level 7, Translational Research Institute
37 Kent Street
Woolloongabba QLD 4102
Query!
Country
Australia
Query!
Secondary sponsor category [1]
302571
0
None
Query!
Name [1]
302571
0
Query!
Address [1]
302571
0
Query!
Country [1]
302571
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
302973
0
Metro South Health Human Research Ethics Committee
Query!
Ethics committee address [1]
302973
0
Metro South Health HREC
Centres for Health Research
Level 7, Translational Research Institute
37 Kent Street
Woolloongabba QLD 4102
Query!
Ethics committee country [1]
302973
0
Australia
Query!
Date submitted for ethics approval [1]
302973
0
18/04/2019
Query!
Approval date [1]
302973
0
21/05/2019
Query!
Ethics approval number [1]
302973
0
Query!
Summary
Brief summary
Alcoholic hepatitis (AH) poses a significant burden on public tertiary hospitals. Medication for AH has recently been demonstrated to be ineffective in a large high-quality study. Sustained alcohol abstinence is the strongest predictor of long-term survival. Behavioural interventions to promote abstinence in AH have not been systematically assessed. We propose to trial an early and intense Cognitive Behavioural Therapy (CBT) program for patients at high risk of poor outcome of alcohol-related liver disease/severe AH and evaluate treatment outcome as a matter of quality assurance.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
92030
0
Prof Jason Connor
Query!
Address
92030
0
Alcohol and Drug Assessment Unit
Princess Alexandra Hospital | Metro South Health
199 Ipswich Road, Woolloongabba Queensland 4102
Query!
Country
92030
0
Australia
Query!
Phone
92030
0
+61 07 31765191
Query!
Fax
92030
0
Query!
Email
92030
0
[email protected]
Query!
Contact person for public queries
Name
92031
0
Dr Jason Coates
Query!
Address
92031
0
Alcohol and Drug Assessment Unit
Princess Alexandra Hospital | Metro South Health
199 Ipswich Road, Woolloongabba Queensland 4102
Query!
Country
92031
0
Australia
Query!
Phone
92031
0
+61 07 3176 5191
Query!
Fax
92031
0
Query!
Email
92031
0
[email protected]
Query!
Contact person for scientific queries
Name
92032
0
Dr Jason Coates
Query!
Address
92032
0
Alcohol and Drug Assessment Unit
Princess Alexandra Hospital | Metro South Health
199 Ipswich Road, Woolloongabba Queensland 4102
Query!
Country
92032
0
Australia
Query!
Phone
92032
0
+61 07 3176 5191
Query!
Fax
92032
0
Query!
Email
92032
0
[email protected]
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Doc. No.
Type
Citation
Link
Email
Other Details
Attachment
1860
Ethical approval
Approved HREC/2019/QMS/51213
377243-(Uploaded-18-06-2020-12-09-22)-Study-related document.pdf
10507
Study protocol
377243-(Uploaded-18-06-2020-12-10-35)-Study-related document.pdf
10508
Informed consent form
377243-(Uploaded-18-06-2020-12-11-14)-Study-related document.pdf
10509
Analytic code
To be attached upon completion of analyses.
10510
Statistical analysis plan
Analysis plan is described in the project descript...
[
More Details
]
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF